- Home
- PDFS vs DMAC Comparison
PDFS vs DMAC Comparison
Compare PDFS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDFS
- DMAC
- Stock Information
- Founded
- PDFS 1992
- DMAC 2000
- Country
- PDFS United States
- DMAC United States
- Employees
- PDFS N/A
- DMAC N/A
- Industry
- PDFS EDP Services
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PDFS Technology
- DMAC Health Care
- Exchange
- PDFS Nasdaq
- DMAC Nasdaq
- Market Cap
- PDFS 789.4M
- DMAC 178.0M
- IPO Year
- PDFS N/A
- DMAC N/A
- Fundamental
- Price
- PDFS $22.50
- DMAC $3.76
- Analyst Decision
- PDFS Strong Buy
- DMAC Strong Buy
- Analyst Count
- PDFS 3
- DMAC 2
- Target Price
- PDFS $33.33
- DMAC $8.00
- AVG Volume (30 Days)
- PDFS 251.5K
- DMAC 307.4K
- Earning Date
- PDFS 08-07-2025
- DMAC 08-06-2025
- Dividend Yield
- PDFS N/A
- DMAC N/A
- EPS Growth
- PDFS N/A
- DMAC N/A
- EPS
- PDFS 0.03
- DMAC N/A
- Revenue
- PDFS $185,933,000.00
- DMAC N/A
- Revenue This Year
- PDFS $23.39
- DMAC N/A
- Revenue Next Year
- PDFS $18.37
- DMAC N/A
- P/E Ratio
- PDFS $634.57
- DMAC N/A
- Revenue Growth
- PDFS 11.75
- DMAC N/A
- 52 Week Low
- PDFS $15.91
- DMAC $2.80
- 52 Week High
- PDFS $39.70
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- PDFS 72.18
- DMAC 47.18
- Support Level
- PDFS $20.74
- DMAC $3.48
- Resistance Level
- PDFS $21.57
- DMAC $3.99
- Average True Range (ATR)
- PDFS 0.67
- DMAC 0.32
- MACD
- PDFS 0.25
- DMAC -0.00
- Stochastic Oscillator
- PDFS 94.87
- DMAC 41.01
About PDFS PDF Solutions Inc.
PDF Solutions Inc offers products and services designed to empower engineers and data scientists across the semiconductor ecosystem to improve the yield, quality, and profitability of their products. The solutions combine proprietary software, physical intellectual property (or IP) for integrated circuit (or IC) designs, electrical measurement hardware tools, various methodologies, and professional services. The company's products and services are sold to integrated device manufacturers (or IDMs), fabless semiconductor companies, foundries, outsourced semiconductor assembly and test (or OSATs), and system houses.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.